The Future of Precision Medicine with Artificial Intelligence

Machine Learning (ML) and Artificial Intelligence (AI) have spread extensively within the last ten years, and the latter can become an essential means to facilitate Precision Medicine (PM). This is one of the ways in which AI contributes to more personalized and effective medical treatments: by analyzing vast, complicated data, it allows the discovery of diagnostic and prognostic biomarkers.

ML enables systems that are not specifically programmed to analyze and learn data, and the efficacy of such systems can be found in fields such as imaging and histopathology. Nevertheless, it has not achieved higher levels of clinical adoption because it suffers from a lack of data integration, infrastructure, and disjointed healthcare environments. Most AI models are only successful in research, and cannot be implemented into the real-life practice yet.

Another big issue is prejudice. Algorithms adopted on either small or homogeneous data can perform poorly on underrepresented groups. Also, Electronic Medical Records (EMRs) are one of the most important data sources that have a tendency to be of low accuracy, non-interoperability, and discontentment by clinicians and are, thus, less useful in AI applications.

Artificial Intelligence in Precision Medicine: Promise, Pitfalls, and Potential:

Modern medicine is becoming dependent on Artificial Intelligence (AI) and especially large language models (LLMs) such as chatbots. A study by Li et al. found out that these systems have the potential to simplify the workflow of healthcare institutions, simplify the routine activities of many jobs, and enable doctors to pay more attention to patients. But these seem like the least of the problems when fast-tracking AI in the medical field regarding safety, bias, and equity.

AI has been successful in the processing of advanced data sets which include lab results and clinical records revealing information that human involvement could not reach. However, ethical and social questions related to the privacy of data, racial discrimination, and lack of equal opportunities in technology are still to be addressed. AI tools are learnt using past data mostly on Caucasian users and therefore can result in erroneous or biased results on the marginalized groups.

Even though AI shows excellent potential, its use in clinical decision-making and the assistance in diagnosis is not quite fully formed. On the one hand, there is still more research that should be conducted, validation that should be provided, and ethical issues that should be explored before AI can be a reliable companion in daily medical practice.

AI in Precision Medicine: Transforming Disease Prevention, Diagnosis, and Treatment

Artificial intelligence (AI) would transform precision medicine (PM) especially in the specialty of cancer and chronic disease management. As indicated in recent study, incorporation of PM into larger population health approaches has the potential to enhance therapy outcomes as well as lower health care expenses. At present, a third of all adults in the European Union have been said to have a chronic illness, a contributor of 75 per cent of all mortality. People in average spend 18 of their last ailing years in at least one disability.

Cancer care is already making use of PM approaches, helping in the diagnosis as well as the treatment of the condition. Nonetheless, most of the disease predictions or prevention prior to symptoms have yet to be fulfilled. The development of genotyping, a decline in the price of genome sequencing, and a popularization of wearable health-monitoring devices are leading what is commonly referred to as the third revolution in medicine. There is a possibility of early detection of the disease and prevention measures mostly in chronic diseases that are provided by these tools.

It is increasingly becoming of interest to determine biomarkers that will indicate the risk of the disease and be addressed before clinical symptoms occur. As an example, warfarin dosing is already derivatised taking genetic information into consideration. The Clinical Pharmacogenetics Implementation Consortium has even devised guidelines about drug dosage depending on the patient genotype. On the same note, genomic characterization of cancer assists physicians to choose better treatment options to treat diseases like breast and lung cancer.

AI in Drug Discovery and Development

The historic drug development process is long-term and expensively spent, and it takes quite a long period to be approved in terms of regulation i.e. more than 10 years. Not only this time period, but also the poor success rates with increasing cost, make the process more than urgent to find a more efficient and quicker method. Artificial Intelligence (AI) has become an invasive power that has the chance to change the way new remedies are researched and commercialized.

Machine learning and deep neural networks to biomedical informatics are AI technologies that are predicted to make a critical acceleration in clinical research. Such tools have a potential to improve image reading, facilitate analysis of electronic health records, workflow of the research, and lead to effective public health measures across the board.

AI has one of the most promising applications in the area of enhancing different points of the drug discovery process.

AI also helps process large volumes of data sources and derive patterns and generate insights that would not be reached with conventional procedures.

AI in Clinical Trials

Current studies indicate the current trend in using artificial intelligence (AI) in clinical trials particularly in treating cancers. To improve screening and diagnosis, predict treatment outcomes, and aiding in combinations therapies selection and optimal dose choices in chemotherapy and immunotherapy, AI is already being applied. These innovations are based on digital pathology, radiology and genomic data.

Nevertheless, efforts to apply AI to healthcare are rather complicated. The critical issues are prejudice and equality in AI systems, socio-environmental factors, data safety, and patient confidentiality, as reported in the literature. The most notable benefits and drawbacks to the application of AI in precision medicine and reveal some of the key aspects to consider in its implementation in the future.

AI in Cancer Diagnosis

Artificial intelligence (AI) is gaining traction in most sectors of the medical profession, such as diagnosing cancer. You can see its origins in any of the pattern recognition back as far as a Lancet report in 1960. Since this time technology has advanced very quickly and the study today is to compare AI system based cancer detection with the traditional method of pathologists. As it happens in most instances, AI systems have proved to be more accurate than human experts when detecting some forms of cancer.

Such as, for instance, AI has shown useful in identifying precancerous polyps in the colon, registering a perceptible decrease in the occurrence of missed cases (by half) via standard colonoscopy approach performed by pathologists. U.S. FDA is one of the organizations that have identified this potential by recently giving the go-ahead to the use of AI tools to detect and diagnose early cancer.

Artificial intelligence is also demonstrating hope in cancer progression inferring. In one study, the AI algorithm accurately determined the risk of bone metastás in 88 percent of breast cancers patients. But to become both accurate and fair, AI screening tools should be trained and checked on the data that exemplifies all groups of the population including ethnic minorities. An overview of AI-based devices applied to scan melanoma revealed that most of the works do not specify the types of skin or ethnicity of the participants. In the absence of such representation, the AI tools will become biased and can also produce inaccurate results on specific populations.

Conclusion

Although the emerging field of artificial intelligence is finally demonstrating potential to improve precision and personalization of clinical trials, there are a few critical challenges that need to be addressed. The journey to fully integrate AI in precision medicine is only in its development stage as it pertains to data interoperability and regulatory issues as well as ethical and social issues. Still, active research in the field of data analytics, wearable, and AI-based modelling keeps creating new opportunities.

Future implementation of AI in the personalized delivery of treatments, the rapid discovery of biomarkers and the real world transformation of monitoring patients will be the subject of discussion in the next article of this series, with examples of how real life systems and healthcare structures are adopting AI standards and solutions, present day trends and influencing regulatory considerations in this field.